Lupin Limited has received United States Food and Drug Administration (USFDA) approval for its abbreviated new drug application for Turqoz (norgestrel and ethinyl estradiol tablets USP) 0.3 mg/0.03 mg.
Lupin can market a generic version of Wyeth Pharmaceuticals LLC’s Lo/Ovral-28, which registers an estimated annual sales of $34 million in the US. The generic product will be manufactured at Lupin’s Pithampur facility in India.
Lupin shares fell by 0.73 per cent to Rs 981 at 12.24 pm on BSE.
This is a Premium article available exclusively to our subscribers.
Subscribe now to and get well-researched and unbiased insights on the Stock market, Economy, Commodities and more...
You have reached your free article limit. Subscribe now to and get well-researched and unbiased insights on the Stock market, Economy, Commodities and more...
You have reached your free article limit. Subscribe now to and get well-researched and unbiased insights on the Stock market, Economy, Commodities and more...
TheHindu Businessline operates by its editorial values to provide you quality journalism.